Windtree Faces Demise From Nasdaq Delisting Over Bid Price Rule Failure

Nasdaq has announced plans to remove Windtree Therapeutics (WINT) from trading, citing non-compliance with listing regulations. The company’s failure to maintain a minimum bid price above $1 per share will lead to the halt of trading on August 21, 2025. This decision comes after the company struggled to sustain its stock value above the required mark. Windtree’s shares have plummeted over recent months and years, currently trading at just $0.11 before being suspended from trading.